U.S. judge supports FDA decision on Eli Lilly’s weight loss drugs

Published 07/05/2025, 17:44
© Reuters.

Investing.com -- A U.S. federal judge has upheld a decision by the U.S. Food and Drug Administration (FDA) to remove Eli Lilly (NYSE:LLY)’s top-selling weight loss and diabetes drugs, Zepbound and Mounjaro, from a list of medicines in short supply. The ruling could affect patients who were hoping to regain access to less expensive versions of these popular treatments.

The FDA’s decision has also impacted compounding pharmacies, which had been permitted to produce hundreds of thousands of doses of obesity drug copies while a shortage was declared by the FDA.

U.S. District Judge Mark Pittman in Texas issued the sealed order on Wednesday in response to a lawsuit filed in October by a compounding industry group against the FDA’s directive. In March, the judge denied a request from compounding pharmacies to continue producing copies of Zepbound and Mounjaro while the lawsuit was ongoing.

As of March 19, all compounding pharmacies, including larger outsourcing facilities, were instructed to stop producing copies of the drugs. A reversed ruling by the judge could have allowed these pharmacies to resume production.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.